Myelodysplastic syndromes

The Lancet

Volumn 383, Issue 9936, 2014, Pages 2239-2252

  Adès, Lionel ^a   Itzykson, Raphael ^a   Fenaux, Pierre ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTARABINE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; TOPOTECAN; ANTINEOPLASTIC AGENT; GROWTH FACTOR; HYPOMETHYLATING AGENT; METHYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

5Q- SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; CHEMOTHERAPY; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CONFERENCE PAPER; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; EPIGENETICS; GENE MUTATION; HEMATOPOIESIS; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPETENT CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW RISK POPULATION; MICROENVIRONMENT; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD EXAMINATION; BLOOD TRANSFUSION; BONE MARROW EXAMINATION; CYTOGENETICS; INCIDENCE; LOW RISK PATIENT; PREDICTION;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; EPIGENESIS, GENETIC; HEMATOPOIESIS; HUMANS; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84903268944     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61901-7     Document Type: Conference Paper

References (160)

1. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364: 2496-506.
2. Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010; 28: 605-13.
3. Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012; 120: 2076-86.
4. Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009; 113: 1315-25.
5. Tefferi A, Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 1872-85.
6. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-51.
7. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-88.
8. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454-65.
9. Neukirchen J, Schoonen WM, Strupp C , et al. Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry. Leuk Res 2011; 35: 1591-96.
10. Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005; 106: 2633-40.
11. Pedersen-Bjergaard J, Daugaard G, Hansen SW, Philip P, Larsen SO, Rorth M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338: 359-63.
12. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fl udarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood 2005; 105: 4573-75.
13. Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fl udarabine and chlorambucil: results of an intergroup study, cancer and l eukemia group B 9011. J Clin Oncol 2002; 20: 3878-84.
14. Iwanaga M, Hsu WL, Soda M, et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011; 29: 428-34.
15. Cardis E, Vrijheid M, Blettner M, et al. Risk of cancer after low doses of ionising radiation: retrospective cohort study in 15 countries. BMJ 2005; 331: 77.
16. Nisse C, Haguenoer JM, Grandbastien B, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Ha ematol 2001; 112: 927-35.
17. Aksoy M, Ozeri S, Sabuncu H, Inanici Y, Yanarda R. Exposure to benzene in Turkey between 1983 and 1985: a haematological study on 231 workers. Br J Ind Med 1987; 44: 785-87.
18. Rigolin GM, Cuneo A, Roberti MG, et al. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. Br J Haematol 1998; 1 03: 189-97.
19. Raza A,Gezer S,Mundle S,et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes Blood 1995 86 268-76
20. Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer 2012; 12: 849-59.
21. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AD. Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 2007; 7: 118-29.
22. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-98.
23. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-38.
24. Tehranchi R, Invernizzi R, Grandien A, et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106: 247-53.
25. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 200 1; 98: 3058-65.
26. Claessens YE, Bouscary D, Dupont JM, et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002; 99: 1594-601.
27. Bhagat TD, Zhou L, Sokol L, et al. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood 2013; 121: 2875-81.
28. Nilsson L, Astrand-Grundström I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 2012-21.
29. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med 2010; 363: 1025-37.
30. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 2002; 99: 4638-41.
31. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 2008; 451: 335-39.
32. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med 2010; 16: 59-66.
33. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010; 16: 49-58.
34. Jä dersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-79.
35. Jerez A, Gondek LP, Jankowska AM, et al. Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. J Clin Oncol 2012; 30: 1343-49.
36. Liu TX, Beck er MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007; 13: 78-83.
37. Joslin JM, Ferna ld AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood 2007; 110: 719-26.
38. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci USA 2009; 106: 12974-79.
39. McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013; 121: 975-83.
40. Gurvich N, Perna F, Farina A, et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability Proc Natl Acad Sci USA 2010 107 22552-57.
41. Aziz A, Baxter EJ, Edwards C, et al. Cooperativity of imprinted genes inactivated by acquired chromosome 20q deletions. J Clin Invest 2013; 123: 2169-82.
42. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12: 599-612.
43. Damm F, Fontenay M, Bernard OA. Point mutations in myelodysplastic syndromes. N Engl J Med 2011; 365: 1154-55, author reply 155.
44. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30: 3376-82.
45. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
46. Quivoron C, CouronnéL, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
47. Papaemmanuil E, Cazzola M, Boultwood J, et al, and the Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Somatic SF3B1 mutation in myelod ysplasia with ring sideroblasts. N Engl J Med 2011; 365: 1384-95.
48. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64-69.
49. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120: 3173-86.
50. Xiao R, Sun Y, Ding JH, et al. Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian or ganogenesis. Mol Cell Biol 2007; 27: 5393-402.
51. Khan H, Vale C, Bhagat T, Verma A. Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol 2013; 50: 16-37.
52. Pérez C, Martínez-Calle N, Martín-Subero JI, et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelo monocytic leukemia. PLoS One 2012; 7: e31605.
53. Marcondes AM, Mhyre AJ, Stirewalt DL, Kim SH, Dinarello CA, Deeg HJ. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelo monocytic leukemia modulates apoptosis and impairs NK function. Proc Natl Acad Sci USA 2008; 105: 2865-70.
54. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010; 464: 852-57.
55. Blau O, Baldus CD, Hofmann WK, et al. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients hav e distinct genetic abnormalities compared with leukemic blasts. Blood 2011; 118: 5583-92.
56. Muguruma Y, Matsushita H, Yahata T, et al. Establishment of a xenograft model of human myelodysplastic syndromes. Haematologica 2011; 96: 543-51.
57. Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4(+) T cells, pro-infl ammatory cytokines and apoptosis are increased in low risk myelodysp lastic syndrome. Br J Haematol 2009; 145: 64-72.
58. Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110: 847-50.
59. Costantini B, Kordasti S, Kulasekararaj AG, et al. The effects of 5-azacytidine on the function and number of regulatory T-cells and T-effectors in myelodysplastic syndrome. Haematologica 2013; 98: 1196-205.
60. Tsai HC, Li H, Van Neste L, et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012; 21: 430-46.
61. Toma A, Fenaux P, Dreyfus F, Cordonnier C. Infections in myelodysplastic syndromes. Haematologica 2012; 97: 1459-70.
62. Hebbar M, Kozlowski D, Wattel E, et al. Association between myelodysplastic syndromes and infl ammatory bowel diseases. Report of seven new cases and review of the literature. Leukemia 1997; 11: 2188-91.
63. Hebbar M, Brouillard M, Wattel E, et al. Association of myelodysplastic syndrome and relapsing polychondritis: further evidence. Leukemia 1995; 9: 731-33.
64. Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27: 754-62.
65. Verburg h E, Achten R, Maes B, et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003; 21: 273-82.
66. Westers TM, Ireland R, Kern W, et al. Standardization of fl ow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26: 1730-41.
67. Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007; 31: 1461-68.
68. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-95.
69. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 1963-70.
70. Braun T, de Botton S, Taksin AL, et al. Characteristics and outcome of myelodyspl astic syndromes (MDS) with isolated 20q deletion: a report on 62 cases. Leuk Res 2011; 35: 863-67.
71. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-81.
72. Maassen A, Strupp C, Giagounidis A, et al. Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts. Leuk Res 2013; 37: 64-70.
73. Malcovati L, Papaemmanuil E, Bowen DT, et al, for the Chronic Myeloid Disorders Working Group of the Internation al Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasm s. Blood 2011; 118: 6239-46.
74. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25: 3503-10.
75. Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22: 538-43.
76. Morel P, Declercq C, Hebbar M, Bauters F, Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mort ality ratio techniques. Br J Haematol 1996; 94: 116-19.
77. Naqvi K, Garcia-Manero G, Sardesai S, et al. Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 2011; 29: 2240-46.
78. Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol 2010; 21: 114-19.
79. Thol F, Friesen I, Damm F, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 2011; 29: 2499-506.
80. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodyspla stic syndromes. Blood 2012; 119: 3578-84.
81. van de Loosdrecht AA, Westers TM, Westra AH, Dräger AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in lo w-and intermediate-1-risk myelodysplastic syndromes by fl ow cytometry. Blood 2008; 111: 1067-77.
82. Germing U, Hildebrandt B, Pfeilstöcker M, et al. Refinement of the international prognostic s coring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005; 19: 2223-31.
83. Malcovati L,Della Porta MG,Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome Haematologica 2006 91 1588-90.
84. Hellström-Lindberg E, Negrin R, Stein R, et al . Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99: 344-51.
85. Kelaidi C, Park S, Sapena R, et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents. Leukemia 2013; 27: 1283-90.
86. Itzykson R, Thépot S, Quesnel B, et al, and the Groupe Francophone des Myelodysplasies(GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azac itidine. Blood 2011; 117: 403-11.
87. Itzykson R, Kosmider O, Cluzeau T, et al, and the Groupe Francophone des Myelodysplasies (GFM). Impact of TET2 mutations on response rate to azacitidine in m yelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147-52.
88. Kulasekararaj AG, Mohamedali AM, Smith AE, et al. Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients. ASH Annual Meeting Abstracts 2010; 116: 125-.
89. Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelody splastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 2013; 160: 660-72.
90. Traina F, Jankowska AM, Visconte V, et al. Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS. ASH Annual Meeting Abstracts 2011; 118: 461.
91. List A, Giagounidis A, Backstrom J, Fu T, Fenaux P. Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q. J Clin Oncol 2011; 29: 6522.
92. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improve d outcome. Blood 2004; 104: 579-85.
93. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-54.
94. Sperr WR, Wimazal F, Kundi M, et al. Survival analysis and AML development in patient s with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems. Ann Hematol 2001; 80: 272-77.
95. Zipperer E, Pelz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 2009; 94: 729-32.
96. Anderson JE, Appelbaum FR, Schoch G, et al. Alloge neic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 1996; 14: 220-26.
97. Arnold R, de Witte T, van Biezen A, et al, for the European Blood and Marrow Transplantation Group. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid l eukemia: an EBMT survey. Bone Marrow Transplant 1998; 21: 1213-16.
98. Sierra J, Pérez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002; 100: 1997-2004.
99. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-51.
100. Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation i n older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31: 2662-70.
101. Knipp S, Hildebrand B, K ündgen A, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007; 110: 345-52.
102. Kantarjian H, Beran M, Cor tes J, et al. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006; 106: 1099-109.
103. Wattel E, Solary E, Leleu X, et al. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Franç ais des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes. Leukemia 1999; 13: 524-29.
104. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin + ara-C-, fl udarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia w ith excess blasts Blood 2001 98 3575-83.
105. Sekeres MA, Maciejewski JP, Erba HP, et al. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2011; 117: 1253-61.
106. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patient s 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99: 4343-49.
107. Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years'experience. Semin Oncol 1987; 14 (suppl 1): 126-33.
108. Fenaux P, Lai J L, Gardin C, Bauters F. Cytogenetics are a predictive factor of response to low dose Ara-C in acute myelogenous leukemia (AML) in the elderly. Leukemia 1990; 4: 312.
109. Fenaux P, Mufti GJ, H ellstrom-Lindberg E, et al, for the International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, o pen-label, phase III study. Lancet Oncol 2009; 10: 223-32.
110. Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azaciti dine compared with low dose ara-C. Br J Haematol 2010; 149: 244-49.
111. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplas tic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429-40.
112. Silverman LR, Fenaux P, Mufti GJ, et al. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer 2011; 117: 2697-702.
113. Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relation ship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica 2013; 98: 1067-72.
114. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794-803.
115. Lü bbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized ph ase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 29: 1987-96.
116. Lee YG, Kim I, Yoon SS, et al, for the Korean Society of Haematology AML/MDS working party. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol 2013; 161: 339-47.
117. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52-57.
118. Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 2009; 27: 3842-48.
119. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with le ukemia. Blood 2006; 108: 3271-79.
120. Silverman L, Verma A, Odchimar-Reissig R, et al. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium. J Clin Oncol 2008; 26: abstr 7000.
121. Prebet T, Gore SD, Su n Z, et al. Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Int ergroup Trial E1905. ASH Annual Meeting Abstracts 2010; 116: 601.
122. Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012; 120: 4945-51.
123. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of mye lodysplastic syndromes and acute myeloid leukemia. Cancer 2008; 113: 1596-604.
124. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with pr eviously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leuk Lymphoma 2008; 49: 2141-47.
125. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012; 26: 381-89.
126. Fenaux P, Rose C. Impact of iron overload in myelodysplastic syndromes. Blood Rev 2009; 23 (suppl 1): S15-19.
127. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemo therapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95: 888-95.
128. Hellström-Lindberg E, Gulbrandsen N, Lindberg G, et al, and the Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120: 1037-46.
129. Pa rk S, Grabar S, Kelaidi C, et al, for the GFM group (Groupe Francophone des Myélodysplasies). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111: 574-82.
130. Jä dersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26: 3607-13.
131. Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: resu lts of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114: 2393-400.
132. Kelaidi C, Park S, Brechignac S, et al, and the Groupe Francophone des Myélodysplasies (GFM). Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008; 32: 1049-53.
133. List A, Dewald G, Bennett J, et al, for the Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-65.
134. Fenaux P, Giagounidis A, Selleslag D, et al, for the MDS-004 Lenalidomide del5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765-76.
135. Giagounidis AA, Kulasekararaj A, Germing U, et al. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide. Leukemia 2012; 26: 855-58.
136. Adé s L, Le Bras F, Sebert M, et al. Treatment with lenalidomide does not appea r to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica 2012; 97: 213-18.
137. Kuendgen A, Lauseker M, List AF, et al. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low-or Intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia 2013; 27: 10 72-79.
138. Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011; 29: 303-09.
139. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for pat ients with myelodysplastic syndrome. Br J Haematol 1997; 99: 699-705.
140. Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodys plasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26: 2505-11.
141. Saunthararajah Y, Nakamura R, Wesley R, Wang Q J, Barrett AJ. A simple method to predict response to immunos uppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102: 3025-27.
142. Silverman LR, McKenzie DR, Peterson BL, et al, for the Cancer and Leukemia Group B. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006; 24: 3895-903.
143. Boehrer S, Beyne-Rauzy O, Prebet T , et al. Interim results of a randomized phase II trial of azacitidine (AZA) +/- epo in lower risk myelodysplastic syndrome (MDS) resistant to an erythropoietic stimulating agent (ESA) alone. Blood 2010; 116: 784.
144. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111 : 86-93.
145. Komrokji RS, Lancet JE, Swern AS, et al. Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. Blood 2012; 120: 3419-24.
146. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-69.
147. Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relatio n between myocardial iron content and chelatable iron pool Blood 2003 101 4632-39.
148. Rose C, Brechignac S, Vassilief D, et al, for the GFM (Groupe Francophone des Myélodysplasies). Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010; 34: 864-70.
149. Leitch HA. Improv ing clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 2007; 31 (suppl 3): S7-9.
150. Neukirchen J, Fox F, K ündgen A, et al. Improved survival in MDS patients receiving iron chelation therapy-A matched pair analysis of 188 patients from the Dü sseldorf MDS registry. Leuk Res 2012; 36: 1067-70.
151. Gattermann N, Porter J, Lopes L, Seymour J. Consensus statement on iron overload in myelodysplastic syndromes. Hematol Oncol Clin North Am 2005; 19 (suppl 1): 18-25.
152. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 2006; 4: 91-96.
153. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. Prognostic impact of pre-transplantation transfusion history and sec ondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2010; 95: 476-84.
154. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586-88.
155. Hellström-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92: 68-75.
156. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-57.
157. Kantarjian H, Fenaux P, Sekeres MA, et al. Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk myelodysplastic syndrome (MDS): update including extended treatment. ASH Annual Meeting Abstracts 2007; 110: 250.
158. Kantarjian HM, Mufti GJ, Fenaux P, et al. Treatment with the thrombopoietin (TPO)-receptor agonist romiplostim in thrombocytopenic pati ents (Pts) with low or intermediate-1 (int-1) risk myelodysplastic syndrome (MDS): follow-up AML and survival results of a randomized, double-blind, placebo (PBO)-controlled study. ASH Annual Meeting Abstracts 2012; 120: 421.
159. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 2007; 21: 1436-41.
160. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk nonsideroblastic myelodysplastic syndromes. Haematologica 2006; 91: 667-70.